find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
351
Clinical Trials
SCLC
Phase I
Enrolling
nct/study# NCT06179069 / ZL-1310-001
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT05684965 / XTX301
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT06276491 / XMAB541-01
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb®541 in Advanced Solid Tumors
Learn More
Advanced Solid Tumors
Phase I/II
Enrolling
nct/study# NCT05584670 / TCD17620
A Phase 1/2, open label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR445877 administered as monotherapy in adults with advanced solid tumors
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT06792552 / SIM0505-101
A PHASE I FIRST-IN-HUMAN, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF SIM0505 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS
Learn More
Skin and Soft Tissue
Phase II/III
Enrolling
nct/study# NCT06947928 / MCC-2021-01
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial of IFx-Hu2.0 as An Adjunctive Therapy to Pembrolizumab in Checkpoint Inhibitor Naïve Subjects with Advanced or Metastatic Merkel Cell Carcinoma
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.